The Technical AnalystExchange: TAI Sector: Healthcare Industry: Biotechnology
Abnova (Taiwan) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.63% TWD31.40
America/New_York / 3 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 901.38 mill |
| EPS: | 0.720 |
| P/E: | 43.61 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 60.55 mill |
| Avg Daily Volume: | 0.157 mill |
| RATING 2024-05-03 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 2.35x |
| Company: PE 43.61 | sector: PE 18.55 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 3.20x |
| Company: PE 43.61 | industry: PE 13.63 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
TWD30.83 (-1.81%) TWD-0.568 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
TWD 30.95 - 31.85 ( +/- 1.42%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD31.40 (-0.63% ) |
| Volume | 0.0995 mill |
| Avg. Vol. | 0.157 mill |
| % of Avg. Vol | 63.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 4133.TW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
4133.TW
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.